Page 8 - சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dependence on Pain Meds and Sedatives Common After Breast Cancer Surgery

December 13, 2020 The risk of becoming dependent on pain medication and sedatives after mastectomy and breast reconstruction surgery is more significant than doctors realized. A study presented this week at the virtual meeting of the San Antonio Breast Cancer Symposium (SABCS) found that people who underwent mastectomy and breast reconstruction were at increased risk of developing dependence on pain and sedative medication. The study showed that 13.1 percent of patients who were not prior opioid users became new persistent opioid users after surgery. Researchers found 6.6 percent of patients who were not prior sedative-hypnotic users became persistent users after surgery. “It’s striking how many patients this is an issue for. It’s more than maybe we would have thought prior to doing the study,” said the lead author, Jacob Cogan, MD, a fellow in hematology-oncology at NewYork-Presbyterian Columbia University Irving Medical Center in New York City.

New yorkUnited statesJacob coganMatteo lambertiniWolgang janniUlm university hospital inUniversity of genovaPresbyterian columbia university irving medical centerSan antonio breast cancer symposiumOpioid crisis response leaves black americansAfter breast cancerNot impossibleSan martino hospitalWhat is chemicalMonitoring breast cancerUlm university hospital

SABCS: Pregnancy Less Likely After Breast Cancer Diagnosis

Dec 15, 2020 MONDAY, Dec. 14, 2020 (HealthDay News) Pregnancy is less likely after prior breast cancer (BC) diagnosis, according to the results of a review presented at the annual San Antonio Breast Cancer Symposium, held virtually from Dec. 8 to 11 . Eva Blondeaux, M.D., from IRCCS Policlinico San Martino Hospital in Genova, Italy, and colleagues conducted a systematic literature review to examine pregnancy after BC, fetal and obstetrical outcomes, disease-free survival (DFS), and overall survival (OS). Data were included from 39 studies with 57,739 women with cancers other than BC and 114,573 women with BC. The researchers found that 7,505 of the BC patients had a pregnancy after BC diagnosis. BC patients had lower chances of having a pregnancy following anticancer treatment completion compared to women from the general population (relative risk, 0.40). BC survivors had significantly increased risks of low birth weight, small for gestational age, preterm delivery, and cesarea

San antonioUnited statesEva blondeauxHealthday newsSan antonio breast cancer symposiumSan martino hospitalசான் அன்டோனியோஒன்றுபட்டது மாநிலங்களில்சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம்சான் மார்டினோ மருத்துவமனை

PreludeDx™ Presents New Data at SABCS Spotlight Session Re-Classifying Patients Meeting RTOG 9804 Low Risk Criteria as Elevated Risk Using DCISionRT®

Share this article Share this article LAGUNA HILLS, Calif., Dec. 15, 2020 /PRNewswire/ Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented clinical outcomes data last week at the San Antonio Breast Cancer Symposium (SABCS) that further validates the DCISionRT® test results of an independent study by Kaiser Permanente Northwest published earlier this year in Clinical Cancer Research. DCISionRT is a biologic risk signature that assess the 10-yr risk of a subsequent breast cancer recurrence. A Spotlight Poster presented at SABCS, showed that the DCISionRT test reclassified 45% of patients meeting RTOG 9804 low risk or good risk criteria for Ductal Carcinoma In Situ (DCIS) as Decision Score (DS) Elevated Risk. These patients who were reclassified by the DCISionRT test to DS Elevated Risk had clinically elevated 10-year breast cancer rates when treated without radiation therapy (RT) and demons

United statesChirag shahAndrew wadeDaniel forcheCory dunnPrnewswire prelude corporation preludedxNational cancer institutePrelude corporationClinical researchUniversity of california san franciscoClinical cancer researchSan antonio breast cancer symposiumKaiser permanente northwestClinical cancerSpotlight posterDuctal carcinoma in situ

CANKADO Service GmbH - press releases

CANKADO Service GmbH - press releases
openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.

Endocrine response predictorSan antonio breast cancer symposiumநாளமில்லா பதில் ப்ரிடிக்டர்சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம்

WSG and CANKADO s EnReP predicts the benefits of anti-hormone

WSG and CANKADO s EnReP predicts the benefits of anti-hormone
openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.

West germanUniversity hospital munichSenology clinic interdisciplinary breast cancer centerOleg gluz breast center niederrheinService gmbh pr agencyHarbeck breast centerHealth medicineGerman study groupUlrike nitz breast center niederrheinHead global business developmentNadia harbeck breast centerService gmbEndocrine response predictorSan antonio breast cancer symposiumBreast centerWest german study group